The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice

Neuropharmacology

Volumn 47, Issue 3, 2004, Pages 390-400

  Shafaroodi, Hamed ^a   Samini, Morteza ^a   Moezi, Leila ^a   Homayoun, Houman ^a   Sadeghipour, Hamed ^a   Tavakoli, Sina ^a   Hajrasouliha, Amir Reza ^a   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cannabinoid; Mice; Opioid; Pentylenetetrazole; Seizure threshold

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; N (2 CYCLOPROPYL) 5,8,11,14 EICOSATETRAENAMIDE; NALTREXONE; NORBINALTORPHIMINE; OPIATE AGONIST; OPIATE ANTAGONIST; PENTETRAZOLE; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL MODEL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SEIZURE THRESHOLD;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; DIFFERENTIAL THRESHOLD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PENTYLENETETRAZOLE; PIPERIDINES; PYRAZOLES; REACTION TIME; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; SEIZURES; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 3242687074     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.04.011     Document Type: Article

References (70)

1. Berman E.F., Alder M.W. The anticonvulsant effect of opioids and opioid peptides against maximal electroshock seizures in rats. Neuropharmacology. 23:1984;367-371
2. Berrendero F., Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl.). 163:2002;111-117
3. Bidaut-Russell M., Howlett A.C. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J. Neurochem. 57:1991;1769-1773
4. Bloom A.S., Dewey W.L. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl.). 57:1978;243-248
5. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le Fur G., Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237:1996;704-711
6. Braida D., Pozzi M., Parolaro D., Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur. J. Pharmacol. 413:2001;227-234
7. Chesher G.B., Jackson D.M. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia. 37:1974;255-264
8. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 48:1991;1991-2003
9. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. N. Y. Acad. Sci. 654:1992;33-51
10. Cichewicz D.L., McCarthy E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 304:2003;1010-1015
11. Cichewicz D.L., Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 305:2003;812-817
12. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. 289:1999;859-867
13. Corchero J., Fuentes J.A., Manzanares J. Delta 9-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur. J. Pharmacol. 323:1997;193-195
14. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res. 287:1983;197-210
15. Frey H.H. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol. Toxicol. 62:1988;150-154
16. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sci. 65:1999;675-685
17. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 22:2002;1146-1154
18. Hayase T., Yamamoto Y., Yamamoto K. Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. J. Pharm. Pharmacol. 53:2001;1525-1532
19. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583
20. Hillard C.J., Manna S., Greenberg M.J., DiCamelli R., Ross R.A., Stevenson L.A., Murphy V., Pertwee R.G., Campbell W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Pharmacol. Exp. Ther. 289:1999;1427-1433
21. Homayoun H., Khavandgar S., Dehpour A.R. Anticonvulsant effects of cyclosporin A on pentylenetetrazole-induced seizure and kindling: modulation by nitricoxidergic system. Brain Res. 939:2002c;1-10
22. Homayoun H., Khavandgar S., Dehpour A.R. The involvement of endogenous opioids and nitricoxidergic pathway in the anticonvulsant effects of foot-shock stress in mice. Epilepsy Res. 49:2002a;131-142
23. Homayoun H., Khavandgar S., Namiranian K., Gaskari S.A., Dehpour A.R. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. 48:2002b;33-41
24. Howlett A.C., Scott D.K., Wilken G.H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol. 38:1989;3297-3304
25. Karler R., Murphy V., Calder L.D., Turkanis S.A. Pentylenetetrazol kindling in mice. Neuropharmacology. 28:1989;775-780
26. Khavandgar S., Homayoun H., Dehpour A.R. Mediation of nitric oxide in inhibitory effect of morphine against electroshock-induced convulsions in mice. Pharmacol. Biochem. Behav. 74:2003;795-801
27. Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia. 42:2001;7-12
28. Kuriyama K., Yoneda Y. Morphine induced alterations of gamma-aminobutyric acid and taurine contents and L-glutamate decarboxylase activity in rat spinal cord and thalamus: possible correlates with analgesic action of morphine. Brain Res. 148:1978;163-179
29. Lambert D.M., Vandevoorde S., Diependaele G., Govaerts S.J., Robert A.R. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 42:2001;321-327
30. Lauretti G.R., Ahmad I., Pleuvry B.J. The activity of opioid analgesics in seizure models utilizing N-methyl-DL-aspartic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology. 33:1994;155-160
31. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404
32. Loscher W., Lehmann H. L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J. Pharmacol. Exp. Ther. 277:1996;1410-1417
33. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III Pentylenetetrazole seizure models. Epilepsy Res. 8:1991;171-189
34. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503
35. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1993;6552-6561
36. Maneuf Y.P., Nash J.E., Crossman A.R., Brotchie J.M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308:1996;161-164
37. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends, Neurosci. 11:1988;308-314
38. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20:1999;287-294
39. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 302:2003;65-67
40. Mas-Nieto M., Pommier B., Tzavara E.T., Caneparo A., Da Nascimento S., Le Fur G., Roques B.P., Noble F. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br. J. Pharmacol. 132:2001;1809-1816
41. Massi P., Vaccani A., Romorini S., Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. Neuroimmunology. 117:2001;116-124
42. Narimatsu S., Yamamoto I., Watanabe K., Yoshimura H. Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances. Eur. J. Pharmacol. 141:1987;437-443
43. Osonoe K., Mori N., Suzuki K., Osonoe M. Antiepileptic effects of inhibitors of nitric oxide syntnase examined in pentylentetrazole-induced seizure in rats. Brain Res. 663:1994;338-340
44. Pavone F., Castellano C., Oliverio A. Strain-dependent effects of shock-induced release of opioids: dissociation between analgesia and behavioral seizures. Brain Res. 366:1986;326-328
45. Pugh G. Jr., Abood M.E., Welch S.P. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res. 689:1995;157-158
46. Puglisi-Allegra S., Cabib S., Oliverio A. Pharmacological evidence for a protective role of the endogenous opioid system on electroshock-induced seizures in the mouse. Neurosci. Lett. 62:1985;241-247
47. Reche I., Fuentes J.A., Ruiz-Gayo M. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Eur. J. Pharmacol. 318:1996;11-16
48. Reche I., Ruiz-Gayo M., Fuentes J.A. Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. Neuropharmacology. 37:1998;215-222
49. Rowen D.W., Embrey J.P., Moore C.H., Welch S.P. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacol. Biochem. Behav. 59:1998;399-404
50. Rubino T., Massi P., Vigano D., Fuzio D., Parolaro D. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci. 66:2000;2213-2219
51. Sagratella S., Massotti M. Convulsant and anticonvulsant effects of opioids: relationship to GABA-mediated transmission. Neuropharmacology. 21:1982;991-1000
52. Shavit Y., Caldecott-Hazard S., Liebeskind J.C. Activating endogenous opioid systems by electroconvulsive shock or footshock stress inhibits recurrent kindled seizures in rats. Brain Res. 305:1984;203-207
53. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334
54. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57:2001;2108-2111
55. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 36:1995;612-626
56. Swinyard E.A., Kupferberg H.J. Antiepileptic drugs: detection, quantification, and evaluation. Fed. Proc. 44:1985;2629-2633
57. Tanda G., Goldberg S.R. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology (Berl.). 169:2003;115-134
58. Thorat S.N., Bhargava H.N. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 260:1994;5-13
59. Turkanis S.A., Chiu P., Borys H.K., Karler R. Influence of delta9-tetrahydrocannabinol and cannabidiol on photically evoked after-discharge potentials. Psychopharmacology (Berl.). 52:1977;207-212
60. Usami N., Kobana K., Yoshida H., Kimura T., Watanabe K., Yoshimura H., Yamamoto I. Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Chem. Pharm. Bull. (Tokyo). 46:1998;1462-1467
61. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 13:2001;1816-1824
62. Vasquez C., Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19:1999;9271-9280
63. Verty A.N., Singh M.E., McGregor I.S., Mallet P.E. The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl.). 168:2003;314-323
64. Vivian J.A., Kishioka S., Butelman E.R., Broadbear J., Lee K.O., Woods J.H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J. Pharmacol. Exp. Ther. 286:1998;697-703
65. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428:2001;51-57
66. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 452:2002;295-301
67. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18
68. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995a;310-321
69. Welch S.P., Dunlow L.D., Patrick G.S., Razdan R.K. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995b;1235-1244
70. Yajima Y., Narita M., Takahashi-Nakano Y., Misawa M., Nagase H., Mizoguchi H., Tseng L.F., Suzuki T. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res. 862:2000;120-126